Skip to main content
. Author manuscript; available in PMC: 2019 Jul 1.
Published in final edited form as: J Immunol. 2018 May 16;201(1):183–192. doi: 10.4049/jimmunol.1701569

Figure 1. The induced TRIM29 plays an important role in producing type I IFN by human mDCs in response to poly I:C.

Figure 1

(A) Human myeloid dendritic cells (mDCs) were purified from PBMCs using a cell sorter. Total RNA was isolated from these primary cells induced or not to realtime PCR. The profile of TRIM29 expression in different cells is indicated. The relative expression of TRIM29 was compared by plotting the values extracted from the gene expression database. A value < 1 indicated the absence of gene expression. (B) Immunoblot analysis of TRIM29 and MABVS in human mDCs treated with control shRNA with a scrambled sequence (sh-Ctrl), shRNA targeting mRNA encoding TRIM29 (two shRNAs: Trim29#1 and Trim29#2) or shRNA targeting mRNA encoding MAVS. GAPDH serves as a loading control throughout. (C) ELISA of IFN-β in human primary mDCs treated with scrambled shRNA (sh-Ctrl) and left unstimulated (Mock) or treated with shRNA as above and then stimulated for 16h with long poly I:C (LPIC, 20 μg/ml) delivered by Lipofectamine 3000. *P<0.05, **P<0.01, ***P<0.001 (unpaired t test). N-STM, cells without stimulation. Data are representative of three independent experiments with similar results (mean + s.d.).